Hepatitis C virus (HCV) infection is a common problem in patients treated with maintenance hemodialysis (HD) and is associated with an increased morbidity and mortality and lower quality of life. The major causes of HCV-associated mortality are liver and cardiovascular-related death. HCVinfected HD patients have a higher prevalence of inflammation-related metabolic and vascular diseases, leading to high rates of cardiovascular mortality in patients with end-stage renal disease. In the current era of highly effective direct-acting antiviral regimens, HCV treatment may also confer hepatic, cardiovascular and other morbidity and mortality benefits even to dialysis-dependent patients who do not qualify for kidney transplantation. Currently, the most accepted regimens in this patient population include elbasvir/grazoprevir and glecaprevir/pibrentasvir
INTRODUCTION
Chronic hepatitis C virus (HCV) infection is one of the major causes of chronic liver disease, affecting over 170 million individuals worldwide. 1 The prevalence of anti-HCV positivity on dialysis varies between 10% and 70%, 2 much higher than in the general population. In the prospective, observational Dialysis Outcomes and Practice Patterns (DOPPS) study of adult hemodialysis (HD) patients randomly selected from 308 dialysis facilities in the developed world, an overall HCV prevalence of 13% was found in 8615 patients 3 although recent estimates suggest the prevalence is declining, currently to 8% in DOPPS 5 (2012 DOPPS 5 ( -2015 . 4 The prevalence of HCV is thought to be declining due to lower rates of blood transfusion due to erythrocyte stimulating agent use, safer blood products supplies in the developed countries that are studied in DOPPS, and possibly due to improvements in infection control practices in HD facilities. transplant waiting list had received anti-HCV therapy during the interferon era. 5 These low rates of HCV treatment may have been related to the unsatisfactory safety profile of interferon and ribavirin treatment regimens, 5, 6 an anticipated low sustained virological response (SVR) rates in the ESRD population, or to an expected lack of clinical benefit of HCV cure in dialysis patients. It is unknown whether this has changed in the current era of the highly effective direct-acting antiviral (DAA) agents with low treatmentassociated adverse event rates.
Previously, the goal of treatment for patients undergoing dialysis was for HCV eradication, particularly for kidney transplant candidates. Treatment was encouraged for HCVinfected patients on the kidney transplant waiting list due to the improved morbidity and mortality of HCV negative kidney transplant recipients when compared with HCV-positive. 7 Moreover, in the interferon era, treatment after transplantation was contraindicated due to high rates of allograft rejection due to the immunomodulatory effect of interferon therapy. 8 Today, with DAA, the discussion has shifted to trying to strategize whether treatment before or after transplantation is the optimal approach on a case-by-case basis.
However, these discussions have neglected a large and important group of patients with ESRD, those who are either not candidates for transplantation or who do not wish to undergo transplant. In this review, we focus on this subset of the dialysis population and explore potential clinical benefits associated with successful HCV eradication in the dialysis population.
HCV infection increases all-cause morbidity and mortality in hemodialysis-dependent patients
The natural history of HCV infection in patients on long-term dialysis is not completely understood. HCV infection in dialysis patients is usually asymptomatic with an apparent indolent course. In ESRD patients on hemodialysis (HD), biochemical evaluation of HCV infection is inaccurate as serum aminotransferase values are typically lower in dialysis patients than in the general population. 2 In a case-control study including 36 patients with HCV on HD, and 37 patients with HCV and normal kidney function; patients with HD had lower levels of transaminases and HCV RNA viral load. 9 Immunologic responses, which are the predominant pathophysiologic mechanism responsible for hepatocyte injury in HCVinfected patients, are lower among patients on long-term dialysis. 10 An exaggerated synthesis of cytokines, including hepatocyte growth factor, 11 tumor necrosis factor-a, interleukin1b, and interleukin-6 12 during the HD session has been hypothesized as a cause for this phenomenon.
Despite a presumed indolent course, HCV antibody positive dialysis patients have an increased risk for allcause mortality compared with uninfected patients. 13 A meta-analysis of 14 observational studies including 145,608 dialysis patients, demonstrated an association between HCV infection and increased mortality, with an adjusted relative risk (ARR) of 1.32 (95% CI 1.24-1.42). The ARR of liver related death in HCV-positive patients was 3.82 (95% CI 1.92-7.61), and was primarily a result of chronic liver disease, complications of cirrhosis and hepatocellular carcinoma.
14 Survival rates in HCVinfected ESRD patients are comparable in patients treated with HD and peritoneal dialysis. 15 
HCV infection increases the risk of developing extrahepatic immune related disorders
In addition to causing chronic liver disease and its complications, HCV infection can lead to serious consequences in other organ systems. HCV can cause mixed cryoglobulinemia syndrome (MCS), with up to 10% to 54% of patients having detectable cryoglobulin levels in the serum, 16, 17 albeit as low as 1% in other studies. 18 About 25% of these patients develop symptoms attributed to MCS. 16 Patients with ESRD are still susceptible to the non-renal manifestations of MCS. Immune complex deposition, leading to vasculitis can occur in the skin, lungs, heart, digestive tract, joints, and brain with various manifestations. Moreover, autoimmune disorders associated with HCV, including Sj€ ogren syndrome, autoimmune thyroid disease, systemic lupus erythematosus, immune thrombocytopenic purpura, and rheumatoid arthritis are found more commonly in this patient population. 19, 20 Patients with HCV are predisposed to malignancies, specifically lymphoma as well as IgM paraproteinemia and Waldenstrom macroglobulinemia. 21 Organ involvement with MCS can be life-threatening and mandates immediate intervention. Because MCS occurs as a sequela of chronic HCV, treatment is aimed at treating the primary infectious etiology, i.e., HCV treatment, in addition to immunosuppressive agents as required.
HCV infection increases cardiovascular morbidity and mortality in hemodialysis-dependent patients
Cardiovascular disease is by far the leading cause of morbidity and mortality in dialysis patients. 22 Cardiovascular mortality rate in ESRD patients is approximately [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] times that observed in the general population. 23 A metaanalysis of 3 studies (n 5 37,787), showed an association between anti-HCV serology positive status and increased cardiovascular mortality.
14 Recently, chronic HCV infection was found to be independently associated with subclinical coronary artherosclerosis in 994 patients with HIV/HCV coinfection. 24 In this study, patients with chronic HCV infection had significantly higher unadjusted prevalence of any plaque on coronary Computed Tomography (CT) angiography.
While the pathogenic processes connecting HCV infection with atherogenesis are not well understood, some studies have demonstrated that serum HCV RNA levels are independently associated with atherosclerosis, 25, 26 though other studies have not confirmed such an association. 27, 28 Nevertheless, systemic inflammation and immune activation have been proposed as potential mechanisms. 26 HCV activates the inflammatory response leading to interleukin 18 production and activation, as seen in patients with acute coronary syndrome. 29, 30 Along this line, HCV-infected patients on HD were found to have lower coronary flow reserve compared to that of noninfected individuals. 31 Chronic HCV infection results in hepatic as well as systemic inflammation with increased levels of atherogenic chemokines and cytokines. 25 The mechanisms whereby HCV infection promotes atherogenesis may be through different biological mechanisms, including HCV colonization and replication within arterial walls, oxidative stress, endotoxemia, cryoglobulinemia, perturbed cellular and humoral immunity, liver steatosis and fibrosis, hyperhomocysteinemia, insulin resistance, and type 2 diabetes. 25 Many of these same processes may also explain the relationship between HCV and increased cardiovascular mortality in both the adult general population and among patients treated with HD. 32 In addition to possible links between HCV infection and cardiovascular disease, a number of investigators have identified associations between HCV infection and cerebrovascular, peripheral vascular, and possibly even renovascular events. In addition to a link between HCV and hypertensive cardiovascular disease 33 and diabetes mellitus, 34 studies have suggested that HCV is a risk factor for carotid atherosclerosis, 35 stroke, 36, 37 and peripheral arterial disease. 38 Please see Figure 1 . A Taiwanese study reported that the risk of fatal cerebrovascular events significantly increased in HCV-infected patients with higher HCV viral load compared with infected patients with lower HCV RNA levels. 37 
HCV and neurological/psychiatric disorders
Emerging evidence suggests a link between HCV infection and neurological and psychiatric disorders, 39 depression and lower quality of life. [39] [40] [41] Chronic HCV infection is also thought to possibly contribute to the higher rates of cognitive impairment seen in HD patients as compared with the general population. 42 Severe impairment on the Mini-Mental Status Examination was more frequent in HD patients with positive HCV serology when compared with uninfected matched controls. 43 These findings may reflect subclinical encephalopathy in HD patients with HCV infection.
DAA therapies in ESRD patients
The increased risk of both liver and cardiovascular disease-related mortality in HCV-infected ESRD patients highlights the need for HCV treatment in this patient population. Moreover, potential treatment benefits for neuropsychiatric disorders could provide an additional impetus for prioritizing HCV treatment in the dialysis population. The development of DAAs to treat HCV infection has resulted in SVR rates exceeding 90% in nearly every patient population infected with HCV. 44 Additionally, hepatically-cleared DAA have opened the door to treatment of patients with ESRD. Currently, daily fixed dose combinations of either elbasvir/grazoprevir (for HCV genotypes 1 and 4) or glecaprevir/pibrentasvir (for HCV genotypes 1 to 6) are approved by the US Food and Drug Administration (FDA) and are recommended by American Association for the Study of Liver Diseases (AASLD) and ISDA guidelines for use in the ESRD population. 45 In the C-SURFER trial, a combination of grazoprevir (NS3/4A protease inhibitor) and elbasvir (NS5A inhibitor) was used to treat HCV genotype 1 in patients with CKD stage 4-5, including HD patients (76% of participants were dialysis dependent). 46 The SVR at 12 weeks post treatment (SVR12) by intention-to-treat [ITT] and modified intention-to-treat mITT analysis were 94% and 99%, respectively. There were no differences in erythropoietin use or other adverse events, in the treatment groups compared to placebo. None of the genotype 1a-infected patients with baseline NS5A RASs (resistant-associated substitutions) experienced viral relapse. While C-SURFER did not evaluate patients with genotype 4 infection, it is likely that the high efficacy of elbasvir/grazoprevir in genotype 1 and 4 infection in persons with normal renal function can be extrapolated to genotype 4-infected persons with CKD stage 4-5.
In EXPEDITION-4 study, the pan-genotypic combination of the NS3/NS4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for genotypes 1-6 were studied. 47 SVR12 by ITT and mITT were 98% and 100%, respectively. There were no virologic failures. Adverse events were mild with pruritus (20%), fatigue (14%), and nausea (12%). This regimen holds considerable promise for the treatment of HCV with all genotypes in ESRD patients.
Sofosbuvir, a potent NS5B inhibitor, is not FDA approved for use for patients with GFR < 30 ml/min/ 1.73m2 because it is renally cleared and sofosbuvir and its metabolites accumulate in patients with reduced GFR. 48 Safe and effective doses of sofosbuvir in persons with an eGFR <30 mL/min/1.73 m 2 have not been established. 45, 49 Studies of reduced dose sofosbuvir in advanced CKD and ESRD have shown lower SVR rates 50, 51 and concern still exists about the safety of full dose sofosbuvir in patients with ESRD. The HCV-TARGET study reported the safety and efficacy of sofosbuvir-containing regimens in patients with advanced CKD (eGFRs: <30 mL/min/1.73m2). 49 Patients received various sofosbuvir-based regimens (peginterferon/ribavirin plus sofosbuvir; simeprevir plus sofosbuvir with and without ribavirin; and sofosbuvir plus ribavirin). Overall, these regimens were well tolerated with no increased discontinuation among patients with low eGFR. The SVR12 rates (81-89%) were similar across the eGFR groups. Notably, progressive deterioration of renal function was observed in a small proportion of the patients with an eGFR <30 mL/min/1.73m2, suggesting the need for close monitoring of these patients. A meta-analysis conducted by Li et al to study the efficacy and safety of DAA regimen in patients with stage 4 and 5 CKD, including dialysis patients, reported high SVR12 of 89.4% and excellent tolerability in strategies containing sofosbuvir. The pooled incidence of serious adverse effects, including anemia and cardiac events, was 12.1% (95% CI 6.2-19.7%). The pooled discontinuation rate because was 2.2% (95% CI 0.8-4.4%). 52 Anemia, Gastrointestinal side effects, fatigue and headache were the most common adverse effects.
The 3D regimen (with or without RBV) achieved rates of SVR between 95% and 100% across a broad range of HCV-infected patients with HCV genotype 1. The RUBY-I study 53 is a an open-label, multicenter, phase 3b, clinical trial investigating the 3D combination of ombitasvir/ Figure 1 Extrarenal complications of hepatitis C in hemodialysis patients.
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Hemodialysis International 2018; 22:S45-S52 paritaprevir (ritonavir)/dasabuvir with or without RBV for the treatment of patients with HCV genotype 1 and CKD stage 4 or 5 (estimated glomerular filtration rate [eGFR] < 30 ml/min/1.73 m2), including those on HD.
Only treatment-naive and noncirrhotic patients were enrolled. The agents compromising the 3D regimen are hepatically metabolized and dose adjustment is not required in patients with CKD. Paritaprevir-ombitasvirdasabuvir (with RBV in HCV genotype 1a and without RBV in HCV genotype 1b) achieved SVR in 18 of 20 patients with an eGFR of 30 mL/min/1.73 m2 or less. When combined with RBV or ritonavir, it carries a greater risk of side effects and drug-drug interactions, respectively. 3D regimen cannot be used in cirrhotic patients with Child-Pugh Class B or C due to risk of decompensated liver disease. This regimen has been largely replaced by newer treatments with less interaction.
Clinical benefits of HCV treatment in ESRD patients
HCV treatment has been associated with clinical benefits in the general population for several years. A landmark study showed SVR to interferon-based treatment among patients with chronic HCV infection and advanced hepatic cirrhosis was associated with lower all-cause mortality. 54 The AASLD and Infectious Diseases Society of America guidelines on HCV recommend treatment of all patients with an expected survival of at least 1 year. Due to the multiple competing risks for mortality in ESRD, it is not certain that these clinical benefits would directly translate to HCV treatment in dialysis patients. Conversely, the soon to be published Kidney Disease: Improving Global Outcomes (KDIGO) guidelines on HCV due not specify a minimum life expectancy for HCV treatment in patients with CKD, in part to reflect a potential bias that could exist resulting in clinicians considering all dialysis patients who are not transplant candidates to have too short of a life expectancy to benefit from treatment. However, emerging evidence seems to suggest that clinical benefits may be derived from HCV treatment in the ESRD population.
To date, some studies have demonstrated that dialysis patients who received antiviral treatment have significant improvements in survival, particularly patients without cirrhosis or hepatocellular carcinoma. 6 The reduction in the risk of mortality in treated patients could potentially be sustained over 3 years 6 The International Dialysis Outcomes and Practice Patterns Survey (DOPPS) enrolling 49,762 patients receiving HD between 1996 and 2011, showed that with antiviral treatment for HCV, the hazard ratio for adjusted all-cause mortality was lower in treated compared with non-treated patients, though not reaching statistical significance (0.47; 95% CI 0.17-1.26). 10 Another study showed that IFN-treated HCV cohort with no cirrhosis or hepatoma have markedly reduced risk of death in the compared with that in the control cohort (hazard ratio 0.17, 95% CI 0.04-0.68). 6 Several studies in patients infected with HCV have found a significant reduction in the risk of acute coronary syndrome, and cerebrovascular events among those who underwent IFNbased antiviral therapy compared to those who did not receive treatment. 6, [55] [56] [57] Use of Interferon-based therapy was associated with multivariate-adjusted hazard ratios of 0.64 (95% CI 0.39-1.06) for Acute coronary syndrome 56 and had significantly reduced the risk of stroke in HCV patients (adjusted HR 5 0.39; 95% CI 0.16-0.95; P 5 0.039). 55 Moreover, achieving SVR12 was found to protect against depression (odds ratio [OR] 5 0.72, P 5 0.008). 58 and results in improved quality of life compared with those who failed treatment. 41, 59 Quality of life measures indicated significantly worse scores for physical function, pain, depression, mental health, vitality, among HCV1 patients. 41 These results are aligned with the current trend toward universal treatment of HCV proposed by World Health Organization.
Timing of treatment
Careful vetting of the decision to treat HCV-infected ESRD patients is critical and the timing of treatment must be made in consideration of kidney transplantation candidacy. In patients who are kidney candidates, multiple management options exist. 60 In patients scheduled to receive a living donor kidney, obtaining a SVR prior to transplant represents a reasonable approach. Alternatively, wait-listed HCV-infected patients may benefit by being consented to receive a kidney from an HCV-positive donor and postponing treatment with DAA therapy until after the transplant. However, in ESRD patients who are not transplant candidates or who do not consent to undergoing kidney transplantation, HCV treatment with DAAs should be considered, as a result of early data that treatment may decrease all-cause mortality and to improve quality of life, as well as to delay the progression of cognitive impairment. However, treatment is not recommended in this patient population solely to reduce the prevalence of HCV in dialysis units, as this can be achieved through standard hygienic precautions to prevent transmission of blood-borne pathogens. 61 
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CONCLUSION
While multiple DAAs have demonstrated efficacy and safety, a critical issue in developing and even developed countries is the cost of these medications. With the advent of newer therapies for HCV, this virus can now be safely and effectively treated in dialysis patients. It is becoming common to treat HCV in dialysis patients who are kidney transplant candidates. We believe that not only renal transplant candidates, but also dialysis patients who are not transplant candidates, are likely to benefit from treatment of HCV infection. HCV infection is associated with multiple adverse clinical outcomes in dialysis patients and early data suggests a benefit of these with treatment. This is an area of desperate need for real-world data and further studies will be required to provide additional evidence of the clinical benefits of treatment in HCV-infected dialysis patients who continue to struggle with poor outcomes and low quality of life.
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